vs
Side-by-side financial comparison of Sanara MedTech Inc. (SMTI) and SYPRIS SOLUTIONS INC (SYPR). Click either name above to swap in a different company.
SYPRIS SOLUTIONS INC is the larger business by last-quarter revenue ($30.3M vs $27.5M, roughly 1.1× Sanara MedTech Inc.). Sanara MedTech Inc. runs the higher net margin — -5.9% vs -12.9%, a 7.0% gap on every dollar of revenue. On growth, Sanara MedTech Inc. posted the faster year-over-year revenue change (4.6% vs -9.5%). Sanara MedTech Inc. produced more free cash flow last quarter ($3.9M vs $-1.5M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs -7.7%).
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.
SMTI vs SYPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.5M | $30.3M |
| Net Profit | $-1.6M | $-3.9M |
| Gross Margin | 93.2% | 4.6% |
| Operating Margin | 23.5% | -10.9% |
| Net Margin | -5.9% | -12.9% |
| Revenue YoY | 4.6% | -9.5% |
| Net Profit YoY | 5.3% | -2992.6% |
| EPS (diluted) | $-0.32 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $27.5M | $30.3M | ||
| Q3 25 | $26.3M | $28.7M | ||
| Q2 25 | $25.8M | $31.4M | ||
| Q1 25 | $23.4M | $29.5M | ||
| Q4 24 | $26.3M | $33.4M | ||
| Q3 24 | $21.7M | $35.7M | ||
| Q2 24 | $20.2M | $35.5M | ||
| Q1 24 | $18.5M | $35.6M |
| Q4 25 | $-1.6M | $-3.9M | ||
| Q3 25 | $-30.4M | $517.0K | ||
| Q2 25 | $-2.0M | $-2.1M | ||
| Q1 25 | $-3.5M | $-899.0K | ||
| Q4 24 | $-1.7M | $135.0K | ||
| Q3 24 | $-2.9M | $390.0K | ||
| Q2 24 | $-3.5M | $16.0K | ||
| Q1 24 | $-1.8M | $-2.2M |
| Q4 25 | 93.2% | 4.6% | ||
| Q3 25 | 92.9% | 7.2% | ||
| Q2 25 | 92.5% | 8.2% | ||
| Q1 25 | 92.2% | 11.4% | ||
| Q4 24 | 91.4% | 16.1% | ||
| Q3 24 | 90.8% | 16.8% | ||
| Q2 24 | 90.0% | 15.9% | ||
| Q1 24 | 89.8% | 8.1% |
| Q4 25 | 23.5% | -10.9% | ||
| Q3 25 | 11.2% | -6.1% | ||
| Q2 25 | -0.1% | -4.6% | ||
| Q1 25 | -8.9% | -0.4% | ||
| Q4 24 | 18.6% | 3.9% | ||
| Q3 24 | 3.6% | 4.8% | ||
| Q2 24 | -14.3% | 3.6% | ||
| Q1 24 | -8.3% | -3.9% |
| Q4 25 | -5.9% | -12.9% | ||
| Q3 25 | -115.5% | 1.8% | ||
| Q2 25 | -7.8% | -6.5% | ||
| Q1 25 | -15.1% | -3.0% | ||
| Q4 24 | -6.5% | 0.4% | ||
| Q3 24 | -13.2% | 1.1% | ||
| Q2 24 | -17.4% | 0.0% | ||
| Q1 24 | -9.5% | -6.2% |
| Q4 25 | $-0.32 | $-0.17 | ||
| Q3 25 | $-3.40 | $0.02 | ||
| Q2 25 | $-0.23 | $-0.09 | ||
| Q1 25 | $-0.41 | $-0.04 | ||
| Q4 24 | $-0.18 | $0.00 | ||
| Q3 24 | $-0.34 | $0.02 | ||
| Q2 24 | $-0.41 | $0.00 | ||
| Q1 24 | $-0.21 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.6M | — |
| Total DebtLower is stronger | $46.0M | — |
| Stockholders' EquityBook value | $5.9M | $17.8M |
| Total Assets | $72.9M | $107.8M |
| Debt / EquityLower = less leverage | 7.74× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.6M | — | ||
| Q3 25 | $14.9M | — | ||
| Q2 25 | $17.0M | — | ||
| Q1 25 | $20.7M | — | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $16.3M | — | ||
| Q2 24 | $6.2M | — | ||
| Q1 24 | $2.8M | — |
| Q4 25 | $46.0M | — | ||
| Q3 25 | $45.1M | — | ||
| Q2 25 | $44.2M | — | ||
| Q1 25 | $43.4M | — | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $14.4M | — | ||
| Q1 24 | $9.7M | — |
| Q4 25 | $5.9M | $17.8M | ||
| Q3 25 | $6.1M | $20.0M | ||
| Q2 25 | $35.4M | $18.7M | ||
| Q1 25 | $36.7M | $19.0M | ||
| Q4 24 | $39.4M | $19.6M | ||
| Q3 24 | $39.8M | $18.2M | ||
| Q2 24 | $41.7M | $19.0M | ||
| Q1 24 | $43.3M | $20.8M |
| Q4 25 | $72.9M | $107.8M | ||
| Q3 25 | $71.1M | $112.5M | ||
| Q2 25 | $98.8M | $105.8M | ||
| Q1 25 | $96.4M | $110.2M | ||
| Q4 24 | $88.1M | $119.4M | ||
| Q3 24 | $88.5M | $121.6M | ||
| Q2 24 | $73.4M | $124.2M | ||
| Q1 24 | $70.9M | $129.0M |
| Q4 25 | 7.74× | — | ||
| Q3 25 | 7.33× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 1.18× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.9M | $-1.1M |
| Free Cash FlowOCF − Capex | $3.9M | $-1.5M |
| FCF MarginFCF / Revenue | 14.0% | -5.0% |
| Capex IntensityCapex / Revenue | 0.3% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.2M | $-6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.9M | $-1.1M | ||
| Q3 25 | $2.2M | $-178.0K | ||
| Q2 25 | $2.7M | $1.1M | ||
| Q1 25 | $-2.0M | $-5.5M | ||
| Q4 24 | $932.0K | $2.3M | ||
| Q3 24 | $2.1M | $-4.8M | ||
| Q2 24 | $-1.4M | $6.2M | ||
| Q1 24 | $-1.6M | $-1.7M |
| Q4 25 | $3.9M | $-1.5M | ||
| Q3 25 | $1.1M | $-390.0K | ||
| Q2 25 | $902.7K | $941.0K | ||
| Q1 25 | $-3.7M | $-5.5M | ||
| Q4 24 | $859.9K | $1.9M | ||
| Q3 24 | $2.0M | $-4.9M | ||
| Q2 24 | $-1.5M | $6.0M | ||
| Q1 24 | $-1.7M | $-2.0M |
| Q4 25 | 14.0% | -5.0% | ||
| Q3 25 | 4.2% | -1.4% | ||
| Q2 25 | 3.5% | 3.0% | ||
| Q1 25 | -15.9% | -18.8% | ||
| Q4 24 | 3.3% | 5.7% | ||
| Q3 24 | 9.4% | -13.8% | ||
| Q2 24 | -7.3% | 16.8% | ||
| Q1 24 | -9.0% | -5.7% |
| Q4 25 | 0.3% | 1.3% | ||
| Q3 25 | 4.0% | 0.7% | ||
| Q2 25 | 6.8% | 0.5% | ||
| Q1 25 | 7.4% | 0.0% | ||
| Q4 24 | 0.3% | 1.2% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 0.3% | 0.5% | ||
| Q1 24 | 0.4% | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | -12.21× | ||
| Q2 24 | — | 385.25× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
